For medically fit patients with metastatic bladder cancer, cisplatin-based combination chemotherapy is the standard of care for first-line treatment. The most common systemic regimens include methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), either classic or dose-dense MVAC regimens, and doublet therapy with cisplatin and gemcitabine. With cisplatin-based combination chemotherapy, the median progression-free survival is 7 months and median overall survival is 15 months. Although bladder cancer is chemotherapy-sensitive, the risk for recurrence is estimated to be up to 61% the first year and up to 78% by year 5.
Compared with single-agent cisplatin therapy, MVAC has demonstrated improved overall response rates, median progression-free survival, and median overall survival, according to Loehrer Sr and colleagues.
The antibody-drug conjugate enfortumab vedotin combined with the checkpoint inhibitor pembrolizumab has shown positive results in a clinical trial among patients with metastatic bladder cancer. Its promising results are predicted to lead to an accelerated approval for this drug regimen as a first-line treatment for people with metastatic bladder cancer who cannot receive cisplatin-based chemotherapy.
Learn more about metastatic bladder cancer management.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Management of Metastatic Bladder Cancer - Medscape - Jan 30, 2023.